Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ono Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the ...

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Japan

◆ Source

Read at ono-pharma.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

Ono Pharmaceutical received manufacturing and marketing approval in Japan for XCOPRI tablets to treat partial-onset seizures, based on a positive multinational Phase 3 clinical study showing significant seizure frequency reduction and manageable safety.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new pathway to enter the Japanese epilepsy treatment market with a clinically validated drug now approved. This approval cuts through local regulatory barriers that often slow market entry for epilepsy therapies.

◆ Coverage

1 source · 16 Sep 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalepilepsyclinical-trialspharmaceuticalsJapan